Eliminationen af toremifen og dets metabolitter var signifikant øget hos patienter med aktiveret leverfunktion og nedsat hos patienter med nedsat leverfunktion.
The elimination of toremifene and its metabolites was significantly increased in patients with activated liver function and decreased in patients with impaired liver function.